Skip to main content

Table 2 Motor nerve conduction measurements

From: Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: A randomized double-blind placebo controlled trial

 

group

Pre-chemotherapy

Post-chemotherapy*

p-value #

Tibial nerve

    

DML(ms)

Omega 3

16.53 (1.95)

17.59 (2.21)

.870

 

Placebo

17.00 (2.16)

17.80 (3.10)

 

a-CMAP(mV)

Omega 3

10.00 (5.18)

11.18 (6.35)

.149

 

Placebo

11.38 (6.08)

10.68 (5.80)

 

MCV(m/s)

Omega 3

46.38 (3.67)

45.16 (4.24)

.359

 

Placebo

46.24 (5.08)

46.03 (6.65)

 

Peroneal nerve

    

DML(ms)

Omega 3

14.16 (1.80)

14.97 (2.53)

.209

 

Placebo

14.85 (3.18)

14.91 (2.37)

 

a-CMAP(mV)

Omega 3

6.20 (6.68)

4.43 (3.26)

.549

 

Placebo

5.51 (3.41)

3.83 (3.15)

 

MCV(m/s)

Omega 3

46.13 (3.32)

45.87 (4.75)

.106

 

Placebo

46.46 (5.24)

42.38 (9.90)

 

Ulnar nerve

    

DML(ms)

Omega 3

9.48 (.74)

9.67 (.86)

.439

 

Placebo

9.67 (.98)

9.60 (1.29)

 

a-CMAP(mV)

Omega 3

17.29 (12.95)

14.25 (3.79)

.256

 

Placebo

13.80 (3.53)

13.29 (4.73)

 

MCV(m/s)

Omega 3

57.30 (5.18)

55.82 (6.35)

.706

 

Placebo

55.80 (4.90)

53.19 (7.29)

 
  1. DML, distal motor latency; a-CMAP, amplitude of compound muscle action potential; MCV, motor conduction velocity.
  2. * One month after the cessation of chemotherapy.
  3. # p value is reported based on the analysis of covariance.